

Author Index Volume 51 (2016)

The issue number is given in front of the pagination

- Abdin, E., M. Subramaniam, E. Achilla, S.A. Chong, J.A. Vaingankar, L. Picco, R. Sambasivam, S. Pang, B.Y. Chua, L.L. Ng, H.C. Chua, D. Heng, M. Prince and P. McCrone, The Societal Cost of Dementia in Singapore: Results from the WiSE Study (2) 439–449
- Abe, M., see Sakai, K. (4) 997–1002
- Aboulkassim, T., see Ongali, B. (4) 1183–1195
- Abu-Hussien, M., see Frenkel-Pinter, M. (1) 165–178
- Achilla, E., see Abdin, E. (2) 439–449
- Acutis, P., see Costassa, E.V. (3) 875–887
- Adam, P., S. Křížková, Z. Heger, P. Babula, V. Pekařík, M. Vaculovičová, C.M. Gomez, R. Kizek and V. Adam, Metallothioneins in Prion- and Amyloid-Related Diseases (3) 637–656
- Adam, V., see Adam, P. (3) 637–656
- Adlard, P.A., see Manso, Y. (1) 81–95
- Adlard, P.A., see Xu, H. (2) 471–487
- Agarwal, A.R., see Nunez, K. (1) 151–163
- Aguayo, L.G., see Peters, C. (3) 689–699
- Akhrif, A., see Pasquini, L. (1) 313–326
- Alberici, A., see Pilotto, A. (2) 563–570
- Alberici, A., see Premi, E. (1) 249–262
- Alcalde-Cabero, E., see de Pedro-Cuesta, J. (4) 1003–1022
- Al-Daghri, N.M., see Manousopoulou, A. (2) 333–338
- Almazán-Isla, J., see de Pedro-Cuesta, J. (4) 1003–1022
- Almeida, O.F.X., see Chang, L. (1) 197–212
- Alyagor, I., see Frenkel-Pinter, M. (1) 165–178
- Andrés-Benito, P., see Aso, E. (2) 489–500
- Andriuta, D., V. Moullart, S. Schraen, A. Devendeville, M.-E. Meyer and O. Godefroy for the Alzheimer's Disease Neuroimaging Initiative, What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects? (3) 793–800
- Anfossi, M., see Montesanto, A. (4) 1265–1274
- Annweiler, C., see Karakis, I. (2) 451–461
- Antonell, A., see Sánchez-Valle, R. (3) 827–835
- Apostolova, L.G., see Rattanabannakit, C. (4) 1145–1155
- Archetti, S., see Premi, E. (1) 249–262
- Asada, T., see Kida, J. (2) 405–415
- Aso, E., P. Andrés-Benito, M. Carmona, R. Maldonado and I. Ferrer, Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine (2) 489–500
- Aspler, J., see Racine, E. (1) 1–9
- Atkinson, R., see Femminella, G.D. (4) 1275–1289
- Avellanal, F., see de Pedro-Cuesta, J. (4) 1003–1022
- Babiloni, C., see Bocchetta, M. (1) 277–291
- Babula, P., see Adam, P. (3) 637–656
- Bagiella, E., see Luchsinger, J.A. (2) 501–514
- Baioni, E., see Costassa, E.V. (3) 875–887
- Bakchine, S., see Godefroy, O. (3) 815–825
- Balasa, M., see Sánchez-Valle, R. (3) 827–835
- Balin, B.J., see Itzhaki, R.F. (4) 979–984
- Ball, M.J., see Itzhaki, R.F. (4) 979–984
- Balzer-Geldsetzer, M., see Heßmann, P. (2) 545–561
- Barak, Y., see Shelef, A. (1) 15–19
- Bargalló, N., see Sánchez-Valle, R. (3) 827–835
- Barocco, F., see Caffarra, P. (1) 27–31
- Barthélemy, N.R., A. Gabelle, C. Hirtz, F. Fenaille, N. Sergeant, S. Schraen-Maschke, J. Vialaret, L. Buée, C. Junot, F. Becher and S. Lehmann, Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies (4) 1033–1043
- Bartolomeo, P., see Migliaccio, R. (4) 1119–1130
- Baruch, Y., see Shelef, A. (1) 15–19
- Bascuñán, D., see Peters, C. (3) 689–699
- Baugh, C.M., see Stern, R.A. (4) 1099–1109
- Baum, E., see Heßmann, P. (2) 545–561
- Beach, T.G., see Dugger, B.N. (2) 345–356
- Beak, S.H., see Kim, Y.H. (1) 293–312

- Bearer, E.L., see Itzhaki, R.F. (4) 979–984
- Becher, F., see Barthélémy, N.R. (4) 1033–1043
- Bechtel, C., see Remington, R. (4) 991–995
- Behnisch, T., see Krishna, K. (3) 783–791
- Beiser, A., see Karakis, I. (2) 451–461
- Belfiore, M., see Manso, Y. (1) 81–95
- Benito-León, J., I. Contador, A.J. Mitchell, Á. Domingo-Santos and F. Bermejo-Pareja, Performance on Specific Cognitive Domains and Cause of Death: A Prospective Population-Based Study in Non-Demented Older Adults (NEDICES) (2) 533–544
- Bennett, S.A.L., see Granger, M.W. (3) 757–773
- Benussi, L., see Bocchetta, M. (1) 277–291
- Berg, D., see Pilotto, A. (2) 563–570
- Berger, U., see Shelef, A. (1) 15–19
- Bermejo-Pareja, F., see Benito-León, J. (2) 533–544
- Bermúdez-Rattoni, F., see Morin, J.-P. (1) 69–79
- Bernardi, L., see Bocchetta, M. (1) 277–291
- Bertoux, M., see Wong, S. (3) 889–903
- Bespalko, A., see Simonovitch, S. (3) 915–927
- Bianchi, M., see Pilotto, A. (2) 563–570
- Bigni, B., see Pilotto, A. (2) 563–570
- Bihaqi, S.W., see Masoud, A.M. (4) 1257–1264
- Binetti, G., see Bocchetta, M. (1) 277–291
- Blanc, F., see Bousiges, O. (4) 1069–1083
- Blanco-Gandía, M.C., see Bonet-Costa, V. (3) 701–711
- Bocchetta, M., A. Mega, L. Bernardi, E. Di Maria, L. Benussi, G. Binetti, B. Borroni, R. Colao, G. Di Fede, S. Fostinelli, D. Galimberti, M. Gennarelli, R. Ghidoni, I. Piaceri, M. Pievani, C. Porteri, V. Redaelli, G. Rossi, S. Suardi, C. Babiloni, E. Scarpini, F. Tagliavini, A. Padovani, B. Nacmias, S. Sorbi, G.B. Frisoni, Sindem, A.C. Bruni, M. Bozzali, L. Parnetti, C. Ferrarese, S.F. Cappa, C. Marra, C. Masullo, I. Rainero, V. Silani, G. Sorrentino, G. Bruno, A. Cagnin, Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol (1) 277–291
- Bogucka-Kocka, A., see Pluta, R. (4) 1023–1031
- Bogucki, J., see Pluta, R. (4) 1023–1031
- Bombois, S., see Grangeon, L. (3) 905–913
- Bonet-Costa, V., V. Herranz-Pérez, M.C. Blanco-Gandía, C. Mas-Bargues, M. Inglés, P. García-Tarraga, M. Rodríguez-Arias, J. Miñarro, C. Borras, J.M. García-Verdugo and J. Viña, Clearing Amyloid- β through PPAR γ /ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease (3) 701–711
- Booth, S.L., see Karakis, I. (2) 451–461
- Borras, C., see Bonet-Costa, V. (3) 701–711
- Borroni, B., see Bocchetta, M. (1) 277–291
- Borroni, B., see Pilotto, A. (2) 563–570
- Borroni, B., see Premi, E. (1) 249–262
- Bosch, B., see Sánchez-Valle, R. (3) 827–835
- Bourre, B., see Grangeon, L. (3) 905–913
- Bousiges, O., B. Cretin, T. Lavaux, N. Philippi, B. Jung, S. Hezard, C. Heitz, C. Demuynck, A. Gabel, C. Martin-Hunyadi and F. Blanc, Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau₁₈₁, total-Tau, A β ₄₂, and A β ₄₀) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies (4) 1069–1083
- Bozzali, M., see Bocchetta, M. (1) 277–291
- Bozzali, M., see Serra, L. (2) 377–389
- Braak, H., see Itzhaki, R.F. (4) 979–984
- Bratasz, A., see Fang, D. (2) 571–580
- Brooks, D.J., see Femminella, G.D. (4) 1275–1289
- Brown, S.A., see Rattanabannakit, C. (4) 1145–1155
- Bruni, A.C., see Bocchetta, M. (1) 277–291
- Bruni, A.C., see Montesanto, A. (4) 1265–1274
- Bruno G., see Bocchetta, M. (1) 277–291
- Brzozowska, J., see Pluta, R. (4) 1023–1031
- Buchert, R., see Suppa, P. (3) 867–873
- Buée, L., see Barthélémy, N.R. (4) 1033–1043
- Bullido, M.J., see Itzhaki, R.F. (4) 979–984
- Bun, S., see Kida, J. (2) 405–415
- Bush, A.I., see Manso, Y. (1) 81–95
- Bush, A.I., see Xu, H. (2) 471–487
- Busigny, T., see Lavallée, M.M. (4) 1225–1236
- Byun, J., see Son, S.M. (4) 1197–1208
- Cadenas, E., see Nunez, K. (1) 151–163
- Caffarra, P., C. Ghetti, L. Ruffini, M. Spallazzi, A. Spotti, F. Barocco, C. Guzzo, M. Marchi and S. Gardini, Brain Metabolism Correlates of The Free and Cued Selective Reminding Test in Mild Cognitive Impairment (1) 27–31
- Cagnin, A., see Bocchetta, M. (1) 277–291
- Cai, Z.-Y., see Xu, Z.-Q. (1) 179–195
- Calero, M., see de Pedro-Cuesta, J. (4) 1003–1022
- Calero, O., see de Pedro-Cuesta, J. (4) 1003–1022
- Caltagirone, C., see Serra, L. (2) 377–389
- Calvó-Perxas, L., see Turró-Garriga, O. (2) 357–366
- Cantu, R.C., see Stern, R.A. (4) 1099–1109
- Cao, L., see Wang, H.-F. (1) 227–236

- Cappa, S.F., see Bocchetta, M. (1) 277–291
 Carare, R.O., see Manousopoulou, A. (2) 333–338
 Carmona, M., see Aso, E. (2) 489–500
 Carrasco, J., see Manso, Y. (1) 81–95
 Carter, C., see Itzhaki, R.F. (4) 979–984
 Casalone, C., see Costassa, E.V. (3) 875–887
 Cascavilla, L., see D’Onofrio, G. (2) 427–437
 Catania, M., see Costassa, E.V. (3) 875–887
 Cauda, F., see Premi, E. (1) 249–262
 Cercignani, M., see Serra, L. (2) 377–389
 Cerón-Solano, G., see Morin, J.-P. (1) 69–79
 Chai, Y.L., H. Kai-Hui Yeo, J. Wang, S. Hilal, M.K.
 Ikram, N. Venketasubramanian, B.-S. Wong
 and C. Li-Hsian Chen, Apolipoprotein ε4 is
 Associated with Dementia and Cognitive
 Impairment Predominantly Due to Alzheimer’s
 Disease and Not with Vascular Cognitive
 Impairment: A Singapore-Based Cohort (4)
 1111–1118
 Chaisson, C., see Stern, R.A. (4) 1099–1109
 Chandler, J., see Racine, E. (1) 1–9
 Chang, H., see Luchsinger, J.A. (2) 501–514
 Chang, L., Y. Zhang, J. Liu, Y. Song, A. Lv, Y. Li,
 W. Zhou, Z. Yan, O.F.X. Almeida and Y. Wu,
 Differential Regulation of N-Methyl-D-Aspar-
 tate Receptor Subunits is An Early Event in the
 Actions of Soluble Amyloid-β_{1–40} Oligomers on
 Hippocampal Neurons (1) 197–212
 Chang, Y.J., see Son, S.M. (4) 1197–1208
 Charidimou, A., see Kim, Y.H. (1) 293–312
 Chau, S.A., J. Chung, N. Herrmann, M. Eizenman
 and K.L. Lanctôt, Apathy and Attentional Bi-
 ases in Alzheimer’s Disease (3) 837–846
 Chen, H., see Chu, S. (2) 525–532
 Chen, H.-Y. and P.K. Panegyres, The Role of Ethnic-
 ity in Alzheimer’s Disease: Findings From The
 C-PATH Online Data Repository (2) 515–523
 Chen, J.-M., see Yao, Q. (4) 1175–1182
 Chen, K., see Xu, L. (4) 1045–1056
 Chen, T., see Hong, X.-P. (2) 605–617
 Chen, Y.-L., see Xu, Z.-Q. (1) 179–195
 Chen, Z.-B., see Hong, X.-P. (2) 605–617
 Cheng, Q., see Yao, Q. (4) 1175–1182
 Cheng, X., see Chu, S. (2) 525–532
 Chieppa, M.N., see Costassa, E.V. (3) 875–887
 Cho, H., see Lyoo, C.H. (3) 671–675
 Choi, J.Y., see Lyoo, C.H. (3) 671–675
 Chong, S.A., see Abdin, E. (2) 439–449
 Chu, S., F. Xu, Y. Su, H. Chen and X. Cheng, Ce-
 rebral Amyloid Angiopathy (CAA)-Related In-
 flammation: Comparison of Inflammatory CAA
 and Amyloid-β-Related Angitis (2) 525–532
 Chua, B.Y., see Abdin, E. (2) 439–449
 Chua, H.C., see Abdin, E. (2) 439–449
 Chuen-Chung Chang, R., see Huang, C. (1) 213–226
 Chukkapalli, S., see Singhrao, S.K. (4) 935–948
 Chung, A., see Song, J.M., (2) 591–604
 Chung, J., see Chau, S.A. (3) 837–846
 Clare, L., C. Quinn, I.R. Jones and R.T. Woods, “I
 Don’t Think Of It As An Illness”: Illness Rep-
 resentations in Mild to Moderate Dementia (1)
 139–150
 Clerici, F., see Grande, G. (1) 57–67
 Clerici, M., see Itzhaki, R.F. (4) 979–984
 Colao, R., see Bocchetta, M. (1) 277–291
 Colao, R., see Montesanto, A. (4) 1265–1274
 Comes, G., see Manso, Y. (1) 81–95
 Conde-Sala, J.L., see Turró-Garriga, O. (2) 357–366
 Conejero-Goldberg, C., see Gomar, J.J. (4) 1085–
 1097
 Contador, I., see Benito-León, J. (2) 533–544
 Copenhaver, P.F., see Gray, N.E. (2) 391–403
 Corona, C., see Costassa, E.V. (3) 875–887
 Cosby, S.L., see Itzhaki, R.F. (4) 979–984
 Cosseddu, M., see Pilotto, A. (2) 563–570
 Costa, T., see Premi, E. (1) 249–262
 Costassa, E.V., M. Fiorini, G. Zanusso, S. Peletto, P.
 Acutis, E. Baioni, C. Maurella, F. Tagliavini,
 M. Catania, M. Gallo, M. Lo Faro, M.N. Chi-
 eppa, D. Meloni, A. D’Angelo, O. Paciello, R.
 Ghidoni, E. Tonoli, C. Casalone and C. Corona,
 Characterization of Amyloid-β Deposits in Bo-
 vine Brains (3) 875–887
 Cottini, E., see Pilotto, A. (2) 563–570
 Cova, I., see Grande, G. (1) 57–67
 Crean, S., see Singhrao, S.K. (4) 935–948
 Cretin, B., see Bousiges, O. (4) 1069–1083
 Crocco, P., see Montesanto, A. (4) 1265–1274
 Cucumo, V., see Grande, G. (1) 57–67
 Cullum, C.M., see LoBue, C. (3) 727–736
 Czuczwar, S.J., see Pluta, R. (4) 1023–1031
 D’Angelo, A., see Costassa, E.V. (3) 875–887
 D’Onofrio, G., F. Panza, D. Sancarlo, F.F. Paris, L.
 Cascavilla, A. Mangiacotti, M. Lauriola, G.H.
 Paroni, D. Seripa and A. Greco, Delusions in
 Patients with Alzheimer’s Disease: A Multidi-
 mensional Approach (2) 427–437
 Dai, S.-X., see Li, W.-X. (2) 417–425
 Dams, J., see Heßmann, P. (2) 545–561

- Davies, P., see Gomar, J.J. (4) 1085–1097
- Davis, S., see Guillot, F. (4) 1157–1173
- De Deyn, P.P., see Niemantsverdriet, E. (1) 97–106
- de la Monte, S.M., see Nunez, K. (1) 151–163
- de la Monte, S.M., see Tong, M. (1) 123–138
- de Nijs, L., see Siersma, A.S.R. (3) 677–682
- de Pedro-Cuesta, J., P. Martínez-Martín, A. Rábano, E. Alcalde-Cabero, F.J.G. López, J. Almazán-Isla, M. Ruiz-Tovar, M.-J. Medrano, F. Avellanal, O. Calero and M. Calero, Drivers: A Biologically Contextualized, Cross-Inferential View of the Epidemiology of Neurodegenerative Disorders (4) 1003–1022
- DeCarli, C., see Karakis, I. (2) 451–461
- Delabrousse-Mayoux, J.-P., see Godefroy, O. (3) 815–825
- Delgado-García, J.M., see Manso, Y. (1) 81–95
- Demuyncck, C., see Bousiges, O. (4) 1069–1083
- Denney, D., see LoBue, C. (3) 727–736
- Dent, K.A., see Xu, H. (2) 471–487
- Deochand, C., see Tong, M. (1) 123–138
- Devanand, D.P., see Luchsinger, J.A. (2) 501–514
- Devendeville, A., see Andriuta, D. (3) 793–800
- Di Fede, G., see Bocchetta, M. (1) 277–291
- Di Maria, E., see Bocchetta, M. (1) 277–291
- Diano, M., see Premi, E. (1) 249–262
- Díaz-Cintra, S., see Morin, J.-P. (1) 69–79
- Didsbury, J., see Tong, M. (1) 123–138
- Dingova, D., T. Fazekas, P. Okuliarova, J. Strbova, M. Kucera and A. Hrabovska, Low Plasma Cholinesterase Activities are Associated with Deficits in Spatial Orientation, Reduced Ability to Perform Basic Activities of Daily Living, and Low Body Mass Index in Patients with Progressed Alzheimer's Disease (3) 801–813
- Dodel, R., see Heßmann, P. (2) 545–561
- Dodge, H.H., see Nishihira, J. (3) 857–866
- Dols, A., see Gossink, F.T. (4) 1249–1256
- Domingo-Santos, Á., see Benito-León, J. (2) 533–544
- Douglas, J.T., see Fang, D. (2) 571–580
- Dreier, A., see Eichler, T. (3) 847–855
- Duan, Y.-J., see Hong, X.-P. (2) 605–617
- Dubois, B., see Migliaccio, R. (4) 1119–1130
- Dubois, B., see Suppa, P. (3) 867–873
- Dugger, B.N., C.M. Whiteside, C.L. Maarouf, D.G. Walker, T.G. Beach, L.I. Sue, A. Garcia, T. Dunckley, B. Meechoovet, E.M. Reiman and A.E. Roher, The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer's Disease (2) 345–356
- Dumurgier, J., see Grangeon, L. (3) 905–913
- Dunckley, T., see Dugger, B.N. (2) 345–356
- Edison, P., see Femminella, G.D. (4) 1275–1289
- Eichler, T., J.R. Thyrian, J. Hertel, S. Richter, D. Wucherer, B. Michalowsky, S. Teipel, I. Kilmann, A. Dreier and W. Hoffmann, Unmet Needs of Community-Dwelling Primary Care Patients with Dementia in Germany: Prevalence and Correlates (3) 847–855
- Eisenbaum, T., see Frenkel-Pinter, M. (1) 165–178
- Eizenman, M., see Chau, S.A. (3) 837–846
- Elahi, M., Z. Hasan, Y. Motoi, S.-E. Matsumoto, K. Ishiguro and N. Hattori, Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice (4) 1209–1224
- Engelborghs, S. see Niemantsverdriet, E. (1) 97–106
- Fan, Z., see Femminella, G.D. (4) 1275–1289
- Fang, D., Z. Zhang, H. Li, Q. Yu, J.T. Douglas, A. Bratasz, P. Kuppusamy and S. ShiDu Yan, Increased Electron Paramagnetic Resonance Signal Correlates with Mitochondrial Dysfunction and Oxidative Stress in an Alzheimer's Disease Mouse Brain (2) 571–580
- Farlow, M.R., see Rattanabannakit, C. (4) 1145–1155
- Fazekas, T., see Dingova, D. (3) 801–813
- Femminella, G.D., S. Ninan, R. Atkinson, Z. Fan, D.J. Brooks and P. Edison, Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer's Disease and Parkinson's Disease Dementia? (4) 1275–1289
- Fenaille, F., see Barthélémy, N.R. (4) 1033–1043
- Ferrarese, C., see Bocchetta, M. (1) 277–291
- Ferrer, I., see Aso, E. (2) 489–500
- Fiebach, J.B., see Suppa, P. (3) 867–873
- Field, H., see Itzhaki, R.F. (4) 979–984
- Finkelstein, D.I., see Xu, H. (2) 471–487
- Fiocco, A.J., see Peck, K.J. (4) 949–959
- Fiorini, M., see Costassa, E.V. (3) 875–887
- Flanagan, E., see Ramanan, S. (2) 367–376
- Flöel, A., see Külzow, N. (3) 713–725
- Florian, H., A. Meier, S. Gauthier, S. Lipschitz, Y. Lin, Q. Tang, A.A. Othman, W.Z. Robieson and L.M. Gault, Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study (4) 1237–1247

- Forlini, C., see Racine, E. (1) 1–9
- Formenti, A., see Pilotto, A. (2) 563–570
- Förstl, H., see Pasquini, L. (1) 313–326
- Fortea, J., see Sánchez-Valle, R. (3) 827–835
- Fostinelli, S., see Bocchetta, M. (1) 277–291
- Fox, N.C., see Pasquier, F. (4) 1131–1143
- Franko, B., see Granger, M.W. (3) 757–773
- Frenkel, D., see Simonovitch, S. (3) 915–927
- Frenkel-Pinter, M., S. Tal, R. Scherzer-Attali, M. Abu-Hussien, I. Alyagor, T. Eisenbaum, E. Gagit and D. Segal, Naphthoquinone-Tryptophan Hybrid Inhibits Aggregation of the Tau-Derived Peptide PHF6 and Reduces Neurotoxicity (1) 165–178
- Frisoni, G.B., see Bocchetta, M. (1) 277–291
- Fritts, N.G., see Stern, R.A. (4) 1099–1109
- Fulop, T., see Itzhaki, R.F. (4) 979–984
- Furmaga-Jabłońska, W., see Pluta, R. (4) 1023–1031
- Gabel, A., see Bousiges, O. (4) 1069–1083
- Gabelle, A., see Barthélémy, N.R. (4) 1033–1043
- Galimberti, D., see Bocchetta, M. (1) 277–291
- Galimberti, D., see Grande, G. (1) 57–67
- Gallea, C., see Migliaccio, R. (4) 1119–1130
- Gallo, M., see Costassa, E.V. (3) 875–887
- Gandini, D., see Lavallée, M.M. (4) 1225–1236
- Gao, S., see Rattanabannakit, C. (4) 1145–1155
- Gao, W.-b., see Yang, C.-c. (1) 33–44
- Gao, Y.-Y., see Xu, Z.-Q. (1) 179–195
- Garbis, S.D., see Manousopoulou, A. (2) 333–338
- Garcia, A., see Dugger, B.N. (2) 345–356
- Garcia-Tarraga, P., see Bonet-Costa, V. (3) 701–711
- Garcia-Verdugo, J.M., see Bonet-Costa, V. (3) 701–711
- Gardini, S., see Caffarra, P. (1) 27–31
- Garre-Olmo, J., see Turró-Garriga, O. (2) 357–366
- Gascón-Bayarri, J. see Turró-Garriga, O. (2) 357–366
- Gasparotti, R., see Premi, E. (1) 249–262
- Gault, L.M., see Florian, H. (4) 1237–1247
- Gauthier, S., see Florian, H. (4) 1237–1247
- Gazit, E., see Frenkel-Pinter, M. (1) 165–178
- Gazzina, S., see Premi, E. (1) 249–262
- Gennarelli, M., see Bocchetta, M. (1) 277–291
- Gerardin, E., see Grangeon, L. (3) 905–913
- Gercel-Taylor, C., see Stern, R.A. (4) 1099–1109
- Ghetti, C., see Caffarra, P. (1) 27–31
- Ghidoni, R., see Bocchetta, M. (1) 277–291
- Ghidoni, R., see Costassa, E.V. (3) 875–887
- Ghiretti, R., see Grande, G. (1) 57–67
- Gil-Kulik, P., see Pluta, R. (4) 1023–1031
- Giralt, M., see Manso, Y. (1) 81–95
- Girard, T.A., see Peck, K.J. (4) 949–959
- Giulietti, G., see Serra, L. (2) 377–389
- Godefroy, O., S. Bakchine, M. Verny, J.-P. Delabrousse-Mayoux, M. Roussel and J.-J. Pere on behalf of the REFLEX study group, Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders (3) 815–825
- Godefroy, O., see Andriuta, D. (3) 793–800
- Goeman, J., see Niemantsverdriet, E. (1) 97–106
- Goldberg, T.E., see Gomar, J.J. (4) 1085–1097
- Gomar, J.J., C. Conejero-Goldberg, P. Davies and T.E. Goldberg for the Alzheimer's Disease Neuroimaging Initiative, Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease (4) 1085–1097
- Gomez, C.M., see Adam, P. (3) 637–656
- Goossens, J., see Niemantsverdriet, E. (1) 97–106
- Gossink, F.T., A. Dols, W.A. Krudop, S.A. Sikkes, C.J. Kerssens, N.D. Prins, P. Scheltens, M.L. Stek and Y.A.L. Pijnenburg, Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia (4) 1249–1256
- Grande, G., V. Cucumo, I. Cova, R. Ghiretti, L. Maggiore, E. Lacorte, D. Galimberti, E. Scarpini, F. Clerici, S. Pomati, N. Vanacore and C. Mariani, Reversible Mild Cognitive Impairment: The Role of Comorbidities at Baseline Evaluation (1) 57–67
- Grangeon, L., C. Paquet, S. Bombois, M. Quillard-Muraine, O. Martinaud, B. Bourre, R. Lefaucheur, G. Nicolas, J. Dumurgier, E. Gerardin, M. Jan, J.-L. Laplanche, K. Peoc'h, J. Hugon, F. Pasquier, D. Maltête, D. Hannequin, D. Wallon and the collaborators of the ePLM.fr group, Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein (3) 905–913
- Granger, M.W., B. Franko, M.W. Taylor, C. Messier, P. St. George-Hyslop and S.A.L. Bennett, A TgCRND8 Mouse Model of Alzheimer's Disease Exhibits Sexual Dimorphisms in Behavioral Indices of Cognitive Reserve (3) 757–773
- Grassi, C., see Itzhaki, R.F. (4) 979–984
- Gray, N.E., J.A. Zweig, C. Kawamoto, J.F. Quinn and P.F. Copenhaver, STX, a Novel Membrane Estrogen Receptor Ligand, Protects Against Amyloid- β Toxicity (2) 391–403
- Greco, A., see D'Onofrio, G. (2) 427–437
- Griffin, W.S.T., see Itzhaki, R.F. (4) 979–984
- Grimmer, T., see Pasquini, L. (1) 313–326

- Grittner, U., see Külzow, N. (3) 713–725
- Gualeni, V., see Premi, E. (1) 249–262
- Guillot, F., S. Kemppainen, G. Lavasseur, P.O. Miettinen, S. Laroche, H. Tanila and S. Davis, Brain-Specific Basal and Novelty-Induced Alternations in PI3K-Akt and MAPK/ERK Signaling in a Middle-Aged A β PP/PS1 Mouse Model of Alzheimer's Disease (4) 1157–1173
- Guo, X., see Xu, L. (4) 1045–1056
- Gurevicius, K., see Leinonen, H. (1) 21–26
- Guzzo, C., see Caffarra, P. (1) 27–31
- Haas, J., see Itzhaki, R.F. (4) 979–984
- Hägerström, D., see Smith, R. (2) 339–343
- Hahn, A., see Külzow, N. (3) 713–725
- Hamel, E. see Ongali, B. (4) 1183–1195
- Hampel, H., see Suppa, P. (3) 867–873
- Han, S.-H., see Moon, Y. (3) 737–745
- Han, Y.-M., see Hong, X.-P. (2) 605–617
- Hannequin, D., see Grangeon, L. (3) 905–913
- Hansson, O., see Smith, R. (2) 339–343
- Harding, A., see Singhrao, S.K. (4) 935–948
- Hart Jr, J., see LoBue, C. (3) 727–736
- Hasan, Z., see Elahi, M. (4) 1209–1224
- Hasegawa, M., see Sakai, K. (4) 997–1002
- Hata, R., see Sakai, K. (4) 997–1002
- Hattori, N., see Elahi, M. (4) 1209–1224
- Haworth, J., M. Phillips, M. Newson, P.J. Rogers, A. Torrens-Burton and A. Tales, Measuring Information Processing Speed in Mild Cognitive Impairment: Clinical Versus Research Dichotomy (1) 263–275
- Heger, Z., see Adam, P. (3) 637–656
- Heitz, C., see Bousiges, O. (4) 1069–1083
- Heng, D., see Abdin, E. (2) 439–449
- Herranz-Pérez, V., see Bonet-Costa, V. (3) 701–711
- Herrmann, N., see Chau, S.A. (3) 837–846
- Hertel, J., see Eichler, T. (3) 847–855
- Heßmann, P., G. Seeberg, J.P. Reese, J. Dams, E. Baum, M.J. Müller, R. Dodel and M. Balzer-Geldsetzer, Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings (2) 545–561
- Hezard, S., see Bousiges, O. (4) 1069–1083
- Hidalgo, J. see Manso, Y. (1) 81–95
- Higashuesato, Y., see Nishihira, J. (3) 857–866
- Hiki, Y., see Sakai, K. (4) 997–1002
- Hilal, S., see Chai, Y.L. (4) 1111–1118
- Himali, J.J., see Karakis, I. (2) 451–461
- Hirtz, C., see Barthélémy, N.R. (4) 1033–1043
- Ho, Y.-S., see Huang, C. (1) 213–226
- Hodges, J.R., see Kumfor, F. (1) 237–248
- Hodges, J.R., see Ramanan, S. (2) 367–376
- Hodges, J.R., see Schubert, S. (3) 775–782
- Hodges, J.R., see Wong, S. (3) 889–903
- Hoe, H.-S., see Song, J.M., (2) 591–604
- Hoffmann, W., see Eichler, T. (3) 847–855
- Holstein, A., see Pasquier, F. (4) 1131–1143
- Holtzman, D.M., see Simonovitch, S. (3) 915–927
- Hong, S.K., see Lyoo, C.H. (3) 671–675
- Hong, X.-P., T. Chen, N.-N. Yin, Y.-M. Han, F. Yuan, Y.-J. Duan, F. Shen, Y.-H. Zhang and Z.-B. Chen, Puerarin Ameliorates D-Galactose Induced Enhanced Hippocampal Neurogenesis and Tau Hyperphosphorylation in Rat Brain (2) 605–617
- Hoogland, G., see Siersma, A.S.R. (3) 677–682
- Hornberger, M., see Ramanan, S. (2) 367–376
- Hornberger, M., see Wong, S. (3) 889–903
- Hrabovska, A., see Dingova, D. (3) 801–813
- Huang, C., O. Tszy-Wa Ng, Y.-S. Ho, M.G. Irwin, R. Chuen-Chung Chang and G. Tin-Chun Wong, Effect of Continuous Propofol Infusion in Rat on Tau Phosphorylation with or without Temperature Control (1) 213–226
- Huang, H., see Xu, Z.-Q. (1) 179–195
- Huang, J.-F., see Li, W.-X. (2) 417–425
- Huang, Y., see Lou, G. (4) 985–990
- Hudson, A.P., see Itzhaki, R.F. (4) 979–984
- Hugon, J., see Grangeon, L. (3) 905–913
- Hwang, M.S., see Lyoo, C.H. (3) 671–675
- Hynan, L.S., see LoBue, C. (3) 727–736
- Ichise, M., see Luchsinger, J.A. (2) 501–514
- Ihara, M., see Manousopoulou, A. (2) 333–338
- Ikejima, C., see Kida, J. (2) 405–415
- Ikezu, T., see Stern, R.A. (4) 1099–1109
- Ikram, M.K., see Chai, Y.L. (4) 1111–1118
- Imboden, H., see Ongali, B. (4) 1183–1195
- Inglés, M., see Bonet-Costa, V. (3) 701–711
- Iram, T., see Simonovitch, S. (3) 915–927
- Irish, M., see Kumfor, F. (1) 237–248
- Irwin, M.G., see Huang, C. (1) 213–226
- Ishiguro, K., see Elahi, M. (4) 1209–1224
- Itzhaki, R.F., R. Lathe, B.J. Balin, M.J. Ball, E.L. Bearer, H. Braak, M.J. Bullido, C. Carter, M. Clerici, S.L. Cosby, K.D. Tredici, H. Field, T. Fulop, C. Grassi, W.S.T. Griffin, J. Haas, A.P. Hudson, A.R. Kamer, D.B. Kell, F. Licastro, L. Letenneur, H. Lövheim, R. Mancuso, J. Miklossy, C. Otth, A.T. Palamara, G. Perry, C. Preston, E. Pretorius, T. Strandberg, N. Tabet,

- S.D. Taylor-Robinson and J.A. Whittum-Hudson, Microbes and Alzheimer's Disease (4) 979–984
- Jabłoński, M., see Pluta, R. (4) 1023–1031
- Jackson, N., see Pasquier, F. (4) 1131–1143
- Jacques, P.F., see Karakis, I. (2) 451–461
- Jan, M., see Grangeon, L. (3) 905–913
- Jang, H.Y., see Kim, Y. (4) 1057–1068
- Januszewski, S., see Pluta, R. (4) 1023–1031
- Jia, J.-P., see Wang, H.-F. (1) 227–236
- Jiang, G.-X., see Yao, Q. (4) 1175–1182
- Jiang, T., see Wang, H.-F. (1) 227–236
- Jiskoot, L.C., see Louwersheimer, E. (2) 581–590
- Joannette, M., see Lavallée, M.M. (4) 1225–1236
- Jögi, J., see Smith, R. (2) 339–343
- Jones, I.R., see Clare, L. (1) 139–150
- Joubert, S., see Lavallée, M.M. (4) 1225–1236
- Joyce, J.A., see Stern, R.A. (4) 1099–1109
- Jung, B., see Bousiges, O. (4) 1069–1083
- Jung, M., see Song, J.M., (2) 591–604
- Junot, C., see Barthélémy, N.R. (4) 1033–1043
- Kai-Hui Yeo, H., see Chai, Y.L. (4) 1111–1118
- Kakuma, T., see Kida, J. (2) 405–415
- Kamer, A.R., see Itzhaki, R.F. (4) 979–984
- Karakis, I., M.P. Pase, A. Beiser, S.L. Booth, P.F. Jacques, G. Rogers, C. DeCarli, R.S. Vasan, T.J. Wang, J.I. Himali, C. Annweiler and S. Sesadri, Association of Serum Vitamin D with the Risk of Incident Dementia and Subclinical Indices of Brain Aging: The Framingham Heart Study (2) 451–461
- Kas, A., see Migliaccio, R. (4) 1119–1130
- Kato, M., see Sakai, K. (4) 997–1002
- Kawaguchi, K., see Sakai, K. (4) 997–1002
- Kawamoto, C., see Gray, N.E. (2) 391–403
- Kay, J., see Nunez, K. (1) 151–163
- Kell, D.B., see Itzhaki, R.F. (4) 979–984
- Kempainen, S., see Guillot, F. (4) 1157–1173
- Kepp, T., see Suppa, P. (3) 867–873
- Kergoat, M.-J., see Lavallée, M.M. (4) 1225–1236
- Kerssens, C.J., see Gossink, F.T. (4) 1249–1256
- Kerti, L., see Külzow, N. (3) 713–725
- Kesavulu, L., see Singhrao, S.K. (4) 935–948
- Ketter, N., see Pasquier, F. (4) 1131–1143
- Keulen, M.A., see Louwersheimer, E. (2) 581–590
- Kida, J., K. Nemoto, C. Ikejima, S. Bun, T. Kakuma, K. Mizukami and T. Asada, Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study (2) 405–415
- Kilimann, I., see Eichler, T. (3) 847–855
- Kim, C., see Kim, Y. (4) 1057–1068
- Kim, J., see Song, J.M., (2) 591–604
- Kim, Y., C. Kim, H.Y. Jang and I. Mook-Jung, Inhibition of Cholesterol Biosynthesis Reduces γ -Secretase Activity and Amyloid- β Generation (4) 1057–1068
- Kim, Y.H., S.H. Beak, A. Charidimou and M. Song, Discovering New Genes in the Pathways of Common Sporadic Neurodegenerative Diseases: A Bioinformatics Approach (1) 293–312
- Kim, Y.J., see Lyoo, C.H. (3) 671–675
- Kitaguchi, N., see Sakai, K. (4) 997–1002
- Kizek, R., see Adam, P. (3) 637–656
- Kocki, J., see Pluta, R. (4) 1023–1031
- Kook, S.Y., see Son, S.M. (4) 1197–1208
- Křížková, S., see Adam, P. (3) 637–656
- Krishna, K., T. Behnisch and S. Sajikumar, Inhibition of Histone Deacetylase 3 Restores Amyloid- β Oligomer-Induced Plasticity Deficit in Hippocampal CA1 Pyramidal Neurons (3) 783–791
- Krotow, A., see Nunez, K. (1) 151–163
- Krudop, W.A., see Gossink, F.T. (4) 1249–1256
- Kuai, X.-x., see Yang, C.-c. (1) 33–44
- Kucera, M., see Dingova, D. (3) 801–813
- Külzow, N., A.V. Witte, L. Kerti, U. Grittner, J.P. Schuchardt, A. Hahn and A. Flöel, Impact of Omega-3 Fatty Acid Supplementation on Memory Functions in Healthy Older Adults (3) 713–725
- Kumfor, F., D. Teo, L. Miller, S. Lah, E. Mioshi, J.R. Hodges, O. Piguet and M. Irish, Examining the Relationship Between Autobiographical Memory Impairment and Carer Burden in Dementia Syndromes (1) 237–248
- Kuo, S.-H., see Wang, H.-L. (1) 45–55
- Kuppusamy, P., see Fang, D. (2) 571–580
- Kuroda, M., see Sakai, K. (4) 997–1002
- Kurz, A., see Pasquini, L. (1) 313–326
- Lacomblez, L., see Migliaccio, R. (4) 1119–1130
- Lacorte, E., see Grande, G. (1) 57–67
- Lacritz, L.H., see LoBue, C. (3) 727–736
- Lah, S., see Kumfor, F. (1) 237–248
- Lanctôt, K.L., see Chau, S.A. (3) 837–846
- Lane, K.A., see Rattanabannakit, C. (4) 1145–1155
- Lange, C., see Suppa, P. (3) 867–873
- Laplanche, J.-L., see Grangeon, L. (3) 905–913
- Laroche, S., see Guillot, F. (4) 1157–1173

- Larsen, D., see Remington, R. (4) 991–995
- Lathe, R., see Itzhaki, R.F. (4) 979–984
- Lauriola, M., see D'Onofrio, G. (2) 427–437
- Lavallée, M.M., D. Gandini, I. Rouleau, G.T. Vallet, M. Joannette, M.-J. Kergoat, T. Busigny, B. Rossion and S. Joubert, A Qualitative Impairment in Face Perception in Alzheimer's Disease: Evidence from a Reduced Face Inversion Effect (4) 1225–1236
- Lavasseur, G., see Guillot, F. (4) 1157–1173
- Lavaux, T., see Bousiges, O. (4) 1069–1083
- Lee, M.S., see Lyoo, C.H. (3) 671–675
- Lefaucheur, R., see Grangeon, L. (3) 905–913
- Lehericy, S., see Migliaccio, R. (4) 1119–1130
- Lehmann, S., see Barthélémy, N.R. (4) 1033–1043
- Leinonen, H., A. Lipponen, K. Gurevicius and H. Tanila, Normal Amplitude of Electroretinography and Visual Evoked Potential Responses in A β PP/PS1 Mice (1) 21–26
- Letenneur, L., see Itzhaki, R.F. (4) 979–984
- Leterme, G.L.P., see Pasquier, F. (4) 1131–1143
- Leyton, C.E., see Ramanan, S. (2) 367–376
- Leyton, C.E., see Schubert, S. (3) 775–782
- Li, G.-H., see Li, W.-X. (2) 417–425
- Li, H., see Fang, D. (2) 571–580
- Li, L., see Yang, C.-c. (1) 33–44
- Li, R., see Xu, L. (4) 1045–1056
- Li, W.-X., S.-X. Dai, J.-Q. Liu, Q. Wang, G.-H. Li and J.-F. Huang, Integrated Analysis of Alzheimer's Disease and Schizophrenia Dataset Revealed Different Expression Pattern in Learning and Memory (2) 417–425
- Li, Y., see Chang, L. (1) 197–212
- Licastro, F., see Itzhaki, R.F. (4) 979–984
- Liepelt-Scarfone, I., see Pilotto, A. (2) 563–570
- Li-Hsian Chen, C., see Chai, Y.L. (4) 1111–1118
- Lin, Y., see Florian, H. (4) 1237–1247
- Lipponen, A., see Leinonen, H. (1) 21–26
- Lipschitz, S., see Florian, H. (4) 1237–1247
- Liu, E., see Pasquier, F. (4) 1131–1143
- Liu, J., see Chang, L. (1) 197–212
- Liu, J.-Q., see Li, W.-X. (2) 417–425
- Liu, N., see Wang, H.-L. (1) 45–55
- Liu, X.-G., see Wang, H.-L. (1) 45–55
- Liu, Y., see Wang, H.-F. (1) 227–236
- Lladó, A., see Sánchez-Valle, R. (3) 827–835
- Lo Faro, M., see Costassa, E.V. (3) 875–887
- LoBue, C., D. Denney, L.S. Hynan, H.C. Rossetti, L.H. Lacritz, J. Hart Jr., K.B. Womack, F.L. Woon and C.M. Cullum, Self-Reported Traumatic Brain Injury and Mild Cognitive Impairment: Increased Risk and Earlier Age of Diagnosis (3) 727–736
- Long, Z., see Xu, L. (4) 1045–1056
- López, F.J.G., see de Pedro-Cuesta, J. (4) 1003–1022
- López-Ramos, J.C., see Manso, Y. (1) 81–95
- Lou, G., Q. Zhang, F. Xiao, Q. Xiang, Z. Su and Y. Huang, Intranasal TAT-haFGF Improves Cognition and Amyloid- β Pathology in an A β PP/PS1 Mouse Model of Alzheimer's Disease (4) 985–990
- Louwersheimer, E., M.A. Keulen, M.D. Steenwijk, M.P. Wattjes, L.C. Jiskoot, H. Vrenken, C.E. Teunissen, B.N.M. van Berckel, W.M. van der Flier, P. Scheltens, J.C. van Swieten and Y.A.L. Pijnenburg, Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease (2) 581–590
- Lövheim, H., see Itzhaki, R.F. (4) 979–984
- Luchsinger, J.A., T. Perez, H. Chang, P. Mehta, J. Steffener, G. Pradabhan, M. Ichise, J. Manly, D.P. Devanand and E. Bagiella, Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial (2) 501–514
- Lv, A., see Chang, L. (1) 197–212
- Lyoo, C.H., H. Cho, J.Y. Choi, M.S. Hwang, S.K. Hong, Y.J. Kim, Y.H. Ryu and M.S. Lee, Tau Accumulation in Primary Motor Cortex of Variant Alzheimer's Disease with Spastic Paraparesis (3) 671–675
- Maarouf, C.L., see Dugger, B.N. (2) 345–356
- Machan, J.T., see Masoud, A.M. (4) 1257–1264
- Maggiore, L., see Grande, G. (1) 57–67
- Magoni, M., see Premi, E. (1) 249–262
- Makovac, E., see Serra, L. (2) 377–389
- Maldonado, R., see Aso, E. (2) 489–500
- Maletta, R., see Montesanto, A. (4) 1265–1274
- Maltête, D., see Grangeon, L. (3) 905–913
- Mancuso, R., see Itzhaki, R.F. (4) 979–984
- Mangiacotti, A., see D'Onofrio, G. (2) 427–437
- Manly, J., see Luchsinger, J.A. (2) 501–514
- Manousopoulou, A., S. Saito, Y. Yamamoto, N.M. Al-Daghri, M. Ihara, R.O. Carare and S.D. Garbis, Hemisphere Asymmetry of Response to Pharmacologic Treatment in an Alzheimer's Disease Mouse Model (2) 333–338
- Manso, Y., G. Comes, J.C. López-Ramos, M. Belfiore, A. Molinero, M. Giralt, J. Carrasco, P.A. Adlard, A.I. Bush, J.M. Delgado-García and J. Hidalgo, Overexpression of Metallothionein-1

- Modulates the Phenotype of the Tg2576 Mouse Model of Alzheimer's Disease (1) 81–95
- Marchi, M., see Caffarra, P. (1) 27–31
- Mariani, C., see Grande, G. (1) 57–67
- Marra, C., see Bocchetta, M. (1) 277–291
- Marra, C., see Serra, L. (2) 377–389
- Marshall, C., see Xu, Z.-Q. (1) 179–195
- Martin, B.M., see Stern, R.A. (4) 1099–1109
- Martin, J.-J., see Niemantsverdriet, E. (1) 97–106
- Martinaud, O., see Grangeon, L. (3) 905–913
- Martínez-Martín, P., see de Pedro-Cuesta, J. (4) 1003–1022
- Martin-Hunyadi, C., see Bousiges, O. (4) 1069–1083
- Mas-Bargues, C., see Bonet-Costa, V. (3) 701–711
- Masliah, E., see Simonovitch, S. (3) 915–927
- Masoud, A.M., S.W. Bihaqi, J.T. Machan, N.H. Zawia and W.E. Renehan, Early-Life Exposure to Lead (Pb) Alters the Expression of microRNA that Target Proteins Associated with Alzheimer's Disease (4) 1257–1264
- Mastropasqua, C., see Serra, L. (2) 377–389
- Masullo, C., see Bocchetta, M. (1) 277–291
- Matsumoto, S.-E., see Elahi, M. (4) 1209–1224
- Mattek, N., see Nishihira, J. (3) 857–866
- Maurella, C., see Costassa, E.V. (3) 875–887
- McCrone, P., see Abdin, E. (2) 439–449
- McDonald, B.C., see Rattanabannakit, C. (4) 1145–1155
- Medrano, M.-J., see de Pedro-Cuesta, J. (4) 1003–1022
- Mechoovet, B., see Dugger, B.N. (2) 345–356
- Mega, A., see Bocchetta, M. (1) 277–291
- Mehta, P., see Luchsinger, J.A. (2) 501–514
- Meier, A., see Florian, H. (4) 1237–1247
- Meloni, D., see Costassa, E.V. (3) 875–887
- Messier, C., see Granger, M.W. (3) 757–773
- Meyer, M.-E., see Andriuta, D. (3) 793–800
- Michaelson, D.M., see Simonovitch, S. (3) 915–927
- Michalowsky, B., see Eichler, T. (3) 847–855
- Michon, A., see Migliaccio, R. (4) 1119–1130
- Miettinen, P.O., see Guillot, F. (4) 1157–1173
- Migliaccio, R., C. Gallea, A. Kas, V. Perlberg, D. Samri, L. Trotta, A. Michon, L. Lacomblez, B. Dubois, S. Lehericy and P. Bartolomeo, Functional Connectivity of Ventral and Dorsal Visual Streams in Posterior Cortical Atrophy (4) 1119–1130
- Miklossy, J., see Itzhaki, R.F. (4) 979–984
- Miller, L., see Kumfor, F. (1) 237–248
- Miñarro, J., see Bonet-Costa, V. (3) 701–711
- Mioshi, E., see Kumfor, F. (1) 237–248
- Mitchell, A.J., see Benito-León, J. (2) 533–544
- Mizukami, K., see Kida, J. (2) 405–415
- Moffat, E., see Song, J.M., (2) 591–604
- Molinero, A., see Manso, Y. (1) 81–95
- Molinuevo, J.L. see Sánchez-Valle, R. (3) 827–835
- Molloy, D.W., see O'Caoimh, R. (2) 619–629
- Monté, G.C., see Sánchez-Valle, R. (3) 827–835
- Montesanto, A., P. Crocco, M. Anfossi, N. Smirne, G. Puccio, R. Colao, R. Maletta, G. Passarino, A.C. Bruni and G. Rose, The Genetic Variability of UCP4 Affects the Individual Susceptibility to Late-Onset Alzheimer's Disease and Modifies the Disease's Risk in APOE-ε4 Carriers (4) 1265–1274
- Mook-Jung, I., see Kim, Y. (4) 1057–1068
- Mook-Jung, I., see Son, S.M. (4) 1197–1208
- Moon, M., see Son, S.M. (4) 1197–1208
- Moon, W.-J., see Moon, Y. (3) 737–745
- Moon, Y., S.-H. Han and W.-J. Moon, Patterns of Brain Iron Accumulation in Vascular Dementia and Alzheimer's Dementia Using Quantitative Susceptibility Mapping Imaging (3) 737–745
- Morin, J.-P., G. Cerón-Solano, G. Velázquez-Campos, G. Pacheco-López, F. Bermúdez-Rattoni and S. Díaz-Cintra, Spatial Memory Impairment is Associated with Intraneuronal Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer's Disease (1) 69–79
- Morrell, C., see Remington, R. (4) 991–995
- Motoi, Y., see Elahi, M. (4) 1209–1224
- Moullart, V., see Andriuta, D. (3) 793–800
- Müller, M.J., see Heßmann, P. (2) 545–561
- Myers, N.E., see Pasquini, L. (1) 313–326
- Nacmias, B., see Bocchetta, M. (1) 277–291
- Nakai, S., see Sakai, K. (4) 997–1002
- Nakanishi, M., T. Nakashima, Y. Shindo, J. Niimura and A. Nishida, Japanese Care Location and Medical Procedures for People with Dementia in the Last Month of Life (3) 747–755
- Nakashima, T., see Nakanishi, M. (3) 747–755
- Nam, J.H., see Song, J.M., (2) 591–604
- Nemoto, K., see Kida, J. (2) 405–415
- Newson, M., see Haworth, J. (1) 263–275
- Ng, L.L., see Abdin, E. (2) 439–449
- Nicolakakis, N., see Ongali, B. (4) 1183–1195
- Nicolas, G., see Grangeon, L. (3) 905–913
- Niemantsverdriet, E., J. Goossens, H. Struyfs, J.-J. Martin, J. Goeman, P.P. De Deyn, H. Vander-

- stichele and S. Engelborghs, Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease (1) 97–106
- Niimura, J., see Nakanishi, M. (3) 747–755
- Ninan, S., see Femminella, G.D. (4) 1275–1289
- Nishida, A., see Nakanishi, M. (3) 747–755
- Nishihira, J., T. Tokashiki, Y. Higashiuessato, D.C. Willcox, N. Mattek, L. Shinto, Y. Ohya and H.H. Dodge, Associations between Serum Omega-3 Fatty Acid Levels and Cognitive Functions among Community-Dwelling Octogenarians in Okinawa, Japan: The KOCOA Study (3) 857–866
- Nunez, K., J. Kay, A. Krotow, M. Tong, A.R. Agarwal, E. Cadena and S.M. de la Monte, Cigarette Smoke-Induced Alterations in Frontal White Matter Lipid Profiles Demonstrated by MALDI-Imaging Mass Spectrometry: Relevance to Alzheimer's Disease (1) 151–163
- O'Caoimh, R., S. Timmons and D.W. Molloy, Screening for Mild Cognitive Impairment: Comparison of "MCI Specific" Screening Instruments (2) 619–629
- Ohlenbusch, A., see Stoeck, K. (3) 683–687
- Ohya, Y., see Nishihira, J. (3) 857–866
- Okuliarova, P., see Dingova, D. (3) 801–813
- Olsen, I., see Singhrao, S.K. (4) 935–948
- Olsson, T., see Smith, R. (2) 339–343
- Ongali, B., N. Nicolakakis, X.-K. Tong, T. Aboulkassim, H. Imboden and E. Hamel, Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease (4) 1183–1195
- Opazo, C., see Peters, C. (3) 689–699
- Ortner, M., see Pasquini, L. (1) 313–326
- Othman, A.A., see Florian, H. (4) 1237–1247
- Otth, C., see Itzhaki, R.F. (4) 979–984
- Pacheco-López, G., see Morin, J.-P. (1) 69–79
- Paciello, O., see Costassa, E.V. (3) 875–887
- Padovani, A. see Premi, E. (1) 249–262
- Padovani, A., see Bocchetta, M. (1) 277–291
- Padovani, A., see Pilotto, A. (2) 563–570
- Page, R., see Remington, R. (4) 991–995
- Pak, D.T.S., see Song, J.M., (2) 591–604
- Palamara, A.T., see Itzhaki, R.F. (4) 979–984
- Paleacu, D., see Shelef, A. (1) 15–19
- Panegyres, P.K., see Chen, H.-Y. (2) 515–523
- Pang, S., see Abdin, E. (2) 439–449
- Panza, F., see D'Onofrio, G. (2) 427–437
- Paquet, C., see Grangeon, L. (3) 905–913
- Paris, F.F., see D'Onofrio, G. (2) 427–437
- Parnetti, L., see Bocchetta, M. (1) 277–291
- Paroni, G.H., see D'Onofrio, G. (2) 427–437
- Pase, M.P., see Karakis, I. (2) 451–461
- Pasquier, F., C. Sadowsky, A. Holstein, G.L.P. Leterme, Y. Peng, N. Jackson, N.C. Fox, N. Ketter, E. Liu, J.M. Ryan and for the ACC-001 (QS-21) Study Team, Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridifaric (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease (4) 1131–1143
- Pasquier, F., see Grangeon, L. (3) 905–913
- Pasquini, L., M. Scherr, M. Tahmasian, N.E. Myers, M. Ortner, A. Kurz, H. Förstl, C. Zimmer, T. Grimmer, A. Akhrif, A.M. Wohlschläger, V. Riedl and C. Sorg, Increased Intrinsic Activity of Medial-Temporal Lobe Subregions is Associated with Decreased Cortical Thickness of Medial-Parietal Areas in Patients with Alzheimer's Disease Dementia (1) 313–326
- Passarino, G., see Montesanto, A. (4) 1265–1274
- Peck, K.J., T.A. Girard, F.A. Russo and A.J. Fiocco, Music and Memory in Alzheimer's Disease and The Potential Underlying Mechanisms (4) 949–959
- Pekařík, V., see Adam, P. (3) 637–656
- Peleotto, S., see Costassa, E.V. (3) 875–887
- Peng, Y., see Pasquier, F. (4) 1131–1143
- Peoc'h, K., see Grangeon, L. (3) 905–913
- Pere, J.-J., see Godefroy, O. (3) 815–825
- Perez, T., see Luchsinger, J.A. (2) 501–514
- Perlberg, V., see Migliaccio, R. (4) 1119–1130
- Perreau, V.M., see Xu, H. (2) 471–487
- Perry, G., see Itzhaki, R.F. (4) 979–984
- Peters, C., D. Bascuñán, C. Opazo and L.G. Aguayo, Differential Membrane Toxicity of Amyloid- β Fragments by Pore Forming Mechanisms (3) 689–699
- Petniak, A., see Pluta, R. (4) 1023–1031
- Philippi, N., see Bousiges, O. (4) 1069–1083
- Phillips, M., see Haworth, J. (1) 263–275
- Piaceri, I., see Bocchetta, M. (1) 277–291
- Picco, L., see Abdin, E. (2) 439–449
- Pievani, M., see Bocchetta, M. (1) 277–291
- Piguet, O., see Kumfor, F. (1) 237–248

- Piguet, O., see Schubert, S. (3) 775–782
- Piguet, O., see Wong, S. (3) 889–903
- Pijnenburg, Y.A.L., see Gossink, F.T. (4) 1249–1256
- Pijnenburg, Y.A.L., see Louwersheimer, E. (2) 581–590
- Pilotto, A., R. Turrone, I. Liepelt-Scarfone, M. Bianchi, L. Poli, B. Borroni, A. Alberici, E. Premi, A. Formenti, B. Bigni, M. Cosseddu, E. Cottini, D. Berg and A. Padovani, Vascular Risk Factors and Cognition in Parkinson's Disease (2) 563–570
- Pinkas-Kramarski, R., see Simonovitch, S. (3) 915–927
- Plopsky, I., see Shelef, A. (1) 15–19
- Pluta, R., J. Kocki, M. Ułamek-Koziół, A. Petniak, P. Gil-Kulik, S. Januszewski, J. Bogucki, M. Jabłoński, J. Brzozowska, W. Furmag-Jabłońska, A. Bogucka-Kocka and S.J. Czuczwar, Discrepancy in Expression of β -Secretase and Amyloid- β Protein Precursor in Alzheimer-Related Genes in the Rat Medial Temporal Lobe Cortex Following Transient Global Brain Ischemia (4) 1023–1031
- Poli, L., see Pilotto, A. (2) 563–570
- Pomati, S., see Grande, G. (1) 57–67
- Porteri, C., see Bocchetta, M. (1) 277–291
- Pradabhan, G., see Luchsinger, J.A. (2) 501–514
- Premi, E., F. Cauda, T. Costa, M. Diano, S. Gazzina, V. Gualeni, A. Alberici, S. Archetti, M. Magoni, R. Gasparotti, A. Padovani and B. Borroni, Looking for Neuroimaging Markers in Fronto-temporal Lobar Degeneration Clinical Trials: A Multi-Voxel Pattern Analysis Study in Granulin Disease (1) 249–262
- Premi, E., see Pilotto, A. (2) 563–570
- Preston, C., see Itzhaki, R.F. (4) 979–984
- Pretorius, E., see Itzhaki, R.F. (4) 979–984
- Prickaerts, J., see Sierksma, A.S.R. (3) 677–682
- Prince, M., see Abdin, E. (2) 439–449
- Prins, N.D., see Gossink, F.T. (4) 1249–1256
- Psychogios, M.N., see Stoeck, K. (3) 683–687
- Puccio, G., see Montesanto, A. (4) 1265–1274
- Quillard-Muraine, M., see Grangeon, L. (3) 905–913
- Quinn, C., see Clare, L. (1) 139–150
- Quinn, J.F., see Gray, N.E. (2) 391–403
- Rábano, A., see de Pedro-Cuesta, J. (4) 1003–1022
- Rabinovici, G.D., see Smith, R. (2) 339–343
- Racine, E., C. Forlini, J. Aspler and J. Chandler, Complementary and Alternative Medicine in the Context of Earlier Diagnoses of Alzheimer's Disease: Opening the Conversation to Prepare Ethical Responses (1) 1–9
- Rainero, I., see Bocchetta, M. (1) 277–291
- Ramanan, S., E. Flanagan, C.E. Leyton, V.L. Villemagne, C.C. Rowe, J.R. Hodges and M. Hornberger, Non-Verbal Episodic Memory Deficits in Primary Progressive Aphasics are Highly Predictive of Underlying Amyloid Pathology (2) 367–376
- Rattanabannakit, C., S.L. Risacher, S. Gao, K.A. Lane, S.A. Brown, B.C. McDonald, F.W. Unverzagt, L.G. Apostolova, A.J. Saykin and M.R. Farlow, The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests (4) 1145–1155
- Redaelli, V., see Bocchetta, M. (1) 277–291
- Reese, J.P., see Heßmann, P. (2) 545–561
- Reiman, E.M., see Dugger, B.N. (2) 345–356
- Remington, R., C. Bechtel, D. Larsen, A. Samar, R. Page, C. Morrell and T.B. Shea, Maintenance of Cognitive Performance and Mood for Individuals with Alzheimer's Disease Following Consumption of a Nutraceutical Formulation: A One-Year, Open-Label Study (4) 991–995
- Renehan, W.E., see Masoud, A.M. (4) 1257–1264
- Reñé-Ramírez, R., see Turró-Garriga, O. (2) 357–366
- Richter, S., see Eichler, T. (3) 847–855
- Riedl, V., see Pasquini, L. (1) 313–326
- Risacher, S.L., see Rattanabannakit, C. (4) 1145–1155
- Robieson, W.Z., see Florian, H. (4) 1237–1247
- Robillard, J.M., The Online Environment: A Key Variable in the Ethical Response to Complementary and Alternative Medicine for Alzheimer's Disease (1) 11–13
- Rodriguez-Arias, M., see Bonet-Costa, V. (3) 701–711
- Rogers, G., see Karakis, I. (2) 451–461
- Rogers, P.J., see Haworth, J. (1) 263–275
- Roher, A.E., see Dugger, B.N. (2) 345–356
- Rose, G., see Montesanto, A. (4) 1265–1274
- Rossetti, H.C., see LoBue, C. (3) 727–736
- Rossi, G., see Bocchetta, M. (1) 277–291
- Rosson, B., see Lavallée, M.M. (4) 1225–1236
- Rouleau, I., see Lavallée, M.M. (4) 1225–1236

- Roussel, M., see Godefroy, O. (3) 815–825
- Rowe, C.C., see Ramanan, S. (2) 367–376
- Ruffini, L., see Caffarra, P. (1) 27–31
- Ruiz-Tovar, M., see de Pedro-Cuesta, J. (4) 1003–1022
- Russo, F.A., see Peck, K.J. (4) 949–959
- Rutten, B.P.F., see Sierksma, A.S.R. (3) 677–682
- Ryan, J.M., see Pasquier, F. (4) 1131–1143
- Ryu, Y.H., see Lyoo, C.H. (3) 671–675
- Sadowsky, C., see Pasquier, F. (4) 1131–1143
- Saito, S., see Manousopoulou, A. (2) 333–338
- Sajikumar, S., see Krishna, K. (3) 783–791
- Sakai, K., T. Senda, R. Hata, M. Kuroda, M. Hasegawa, M. Kato, M. Abe, K. Kawaguchi, S. Nakai, Y. Hiki, Y. Yuzawa and N. Kitaguchi, Patients that have Undergone Hemodialysis Exhibit Lower Amyloid Deposition in the Brain: Evidence Supporting a Therapeutic Strategy for Alzheimer's Disease by Removal of Blood Amyloid (4) 997–1002
- Sala-Llonch, R., see Sánchez-Valle, R. (3) 827–835
- Samar, A., see Remington, R. (4) 991–995
- Sambasivam, R., see Abdin, E. (2) 439–449
- Samri, D., see Migliaccio, R. (4) 1119–1130
- Sancarlo, D., see D'Onofrio, G. (2) 427–437
- Sánchez-Valle, R., G.C. Monté, R. Sala-Llonch, B. Bosch, J. Fortea, A. Lladó, A. Antonell, M. Balasa, N. Bargalló and J.L. Molinuevo, White Matter Abnormalities Track Disease Progression in *PSEN1* Autosomal Dominant Alzheimer's Disease (3) 827–835
- Savage, G., see Wong, S. (3) 889–903
- Saykin, A.J., see Rattanabannakit, C. (4) 1145–1155
- Scarpini, E., see Bocchetta, M. (1) 277–291
- Scarpini, E., see Grande, G. (1) 57–67
- Scheltens, P., see Gossink, F.T. (4) 1249–1256
- Scheltens, P., see Louwersheimer, E. (2) 581–590
- Scherr, M., see Pasquini, L. (1) 313–326
- Scherzer-Attali, R., see Frenkel-Pinter, M. (1) 165–178
- Schilling, M.A., Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease (4) 961–977
- Schmidt, J., see Stoeck, K. (3) 683–687
- Schmukler, E., see Simonovitch, S. (3) 915–927
- Schraen, S., see Andriuta, D. (3) 793–800
- Schraen-Maschke, S., see Barthélémy, N.R. (4) 1033–1043
- Schubert, S., C.E. Leyton, J.R. Hodges and O. Piguet, Longitudinal Memory Profiles in Behavioral- Variant Frontotemporal Dementia and Alzheimer's Disease (3) 775–782
- Schuchardt, J.P., see Külzow, N. (3) 713–725
- Seeberg, G., see Heßmann, P. (2) 545–561
- Segal, D., see Frenkel-Pinter, M. (1) 165–178
- Senda, T., see Sakai, K. (4) 997–1002
- Sergeant, N., see Barthélémy, N.R. (4) 1033–1043
- Seripa, D., see D'Onofrio, G. (2) 427–437
- Serra, L., M. Cercignani, C. Mastropasqua, M. Torso, B. Spanò, E. Makovac, V. Viola, G. Giulietti, C. Marra, C. Caltagirone and M. Bozzali, Longitudinal Changes in Functional Brain Connectivity Predicts Conversion to Alzheimer's Disease (2) 377–389
- Seshadri, S., see Karakis, I. (2) 451–461
- Shah, S., see Stern, R.A. (4) 1099–1109
- Shaw, L.M., see White, M.T. (2) 463–470
- Shea, T.B., see Remington, R. (4) 991–995
- Shelef, A., Y. Barak, U. Berger, D. Paleacu, S. Tadger, I. Plopsky and Y. Baruch, Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study (1) 15–19
- Shen, F., see Hong, X.-P. (2) 605–617
- ShiDu Yan, S., see Fang, D. (2) 571–580
- Shin, H.-J., see Son, S.M. (4) 1197–1208
- Shindo, Y., see Nakanishi, M. (3) 747–755
- Shinto, L., see Nishihira, J. (3) 857–866
- Sierksma, A.S.R., L. de Nijs, G. Hoogland, T. Vanmerlo, F.W. van Leeuwen, B.P.F. Rutten, H.W.M. Steinbusch, J. Prickaerts and D.L.A. van den Hove, Fluoxetine Treatment Induces Seizure Behavior and Premature Death in APPswe/PS-1dE9 Mice (3) 677–682
- Sikkes, S.A., see Gossink, F.T. (4) 1249–1256
- Silani, V., see Bocchetta, M. (1) 277–291
- Simonovitch, S., E. Schmukler, A. Bespalko, T. Iram, D. Frenkel, D.M. Holtzman, E. Masliah, D.M. Michaelson and R. Pinkas-Kramarski, Impaired Autophagy in APOE4 Astrocytes (3) 915–927
- SINdem, see Bocchetta, M. (1) 277–291
- Singh, N., see Tripathi, A.K. (1) 107–121
- Singhrao, S.K., A. Harding, S. Chukkapalli, I. Olsen, L. Kesavulu and S. Crean, Apolipoprotein E Related Co-Morbidities and Alzheimer's Disease (4) 935–948
- Small, D.H., see Southam, K.A. (3) 657–669
- Smirne, N., see Montesanto, A. (4) 1265–1274
- Smith, R., M. Wibom, T. Olsson, D. Hägerström, J. Jögi, G.D. Rabinovici and O. Hansson, Posterior Accumulation of Tau and Concordant Hy-

- pometabolism in an Early-Onset Alzheimer's Disease Patient with *Presenilin-1* Mutation (2) 339–343
- Son, S.M., H.-J. Shin, J. Byun, S.Y. Kook, M. Moon, Y.J. Chang and I. Mook-Jung, Metformin Facilitates Amyloid- β Generation by β - and γ -Secretases via Autophagy Activation (4) 1197–1208
- Song, J.M., Y.M. Sung, J.H. Nam, H. Yoon, A. Chung, E. Moffat, M. Jung, D.T.S. Pak, J. Kim and H.-S. Hoe, A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Increases Dendritic Spine Density via RasGRF1/ERK Pathway (2) 591–604
- Song, M., see Kim, Y.H. (1) 293–312
- Song, Q.-Y., see Wang, H.-L. (1) 45–55
- Song, Y., see Chang, L. (1) 197–212
- Sorbi, S., see Bocchetta, M. (1) 277–291
- Sorg, C., see Pasquini, L. (1) 313–326
- Sorrentino, G., see Bocchetta, M. (1) 277–291
- Southam, K.A., A.J. Vincent and D.H. Small, Do Microglia Default on Network Maintenance in Alzheimer's Disease? (3) 657–669
- Spallazzi, M., see Caffarra, P. (1) 27–31
- Spanò, B., see Serra, L. (2) 377–389
- Spies, L., see Suppa, P. (3) 867–873
- Spotti, A., see Caffarra, P. (1) 27–31
- St. George-Hyslop, P., see Granger, M.W. (3) 757–773
- Steenwijk, M.D., see Louwersheimer, E. (2) 581–590
- Steffener, J., see Luchsinger, J.A. (2) 501–514
- Steinbusch, H.W.M., see Sierksma, A.S.R. (3) 677–682
- Steinfeld, R., see Stoeck, K. (3) 683–687
- Stek, M.L., see Gossink, F.T. (4) 1249–1256
- Stern, R.A., Y. Tripodis, C.M. Baugh, N.G. Fritts, B.M. Martin, C. Chaisson, R.C. Cantu, J.A. Joyce, S. Shah, T. Ikezu, J. Zhang, C. Gercel-Taylor and D.D. Taylor, Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy (4) 1099–1109
- Stoeck, K., M.N. Psychogios, A. Ohlenbusch, R. Steinfeld and J. Schmidt, Late-Onset Metachromatic Leukodystrophy with Early Onset Dementia Associated with a Novel Missense Mutation in the Arylsulfatase A Gene (3) 683–687
- Strandberg, T., see Itzhaki, R.F. (4) 979–984
- Strbova, J., see Dingova, D. (3) 801–813
- Struyfs, H., see Niemantsverdriet, E. (1) 97–106
- Su, Y., see Chu, S. (2) 525–532
- Su, Z., see Lou, G. (4) 985–990
- Suardi, S., see Bocchetta, M. (1) 277–291
- Subramaniam, M., see Abdin, E. (2) 439–449
- Sue, L.I., see Dugger, B.N. (2) 345–356
- Sung, Y.M., see Song, J.M., (2) 591–604
- Suppa, P., H. Hampel, T. Kepp, C. Lange, L. Spies, J.B. Fiebach, B. Dubois and R. Buchert for the Alzheimer's Disease Neuroimaging Initiative, Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment (3) 867–873
- Tabet, N., see Itzhaki, R.F. (4) 979–984
- Tadger, S., see Shelef, A. (1) 15–19
- Tagliavini, F., see Bocchetta, M. (1) 277–291
- Tagliavini, F., see Costassa, E.V. (3) 875–887
- Tahmasian, M., see Pasquini, L. (1) 313–326
- Tal, S., see Frenkel-Pinter, M. (1) 165–178
- Tales, A., see Haworth, J. (1) 263–275
- Tan, L., see Wang, H.-F. (1) 227–236
- Tan, M.-S., see Wang, H.-F. (1) 227–236
- Tang, Q., see Florian, H. (4) 1237–1247
- Tanila, H., see Guillot, F. (4) 1157–1173
- Tanila, H., see Leinonen, H. (1) 21–26
- Taylor, D.D., see Stern, R.A. (4) 1099–1109
- Taylor, M.W., see Granger, M.W. (3) 757–773
- Taylor-Robinson, S.D., see Itzhaki, R.F. (4) 979–984
- Teipel, S., see Eichler, T. (3) 847–855
- Teo, D., see Kumfor, F. (1) 237–248
- Teunissen, C.E., see Louwersheimer, E. (2) 581–590
- Thyrian, J.R., see Eichler, T. (3) 847–855
- Timmons, S., see O'Caoimh, R. (2) 619–629
- Tin-Chun Wong, G., see Huang, C. (1) 213–226
- Tokashiki, T., see Nishihira, J. (3) 857–866
- Tong, M., C. Deochand, J. Didsbury and S.M. de la Monte, T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease (1) 123–138
- Tong, M., see Nunez, K. (1) 151–163
- Tong, X.-K., see Ongali, B. (4) 1183–1195
- Tonoli, E., see Costassa, E.V. (3) 875–887
- Torrens-Burton, A., see Haworth, J. (1) 263–275
- Torso, M., see Serra, L. (2) 377–389
- Tredici, K.D., see Itzhaki, R.F. (4) 979–984
- Tripathi, A.K. and N. Singh, Prion Protein-Hemin Interaction Upregulates Hemoglobin Synthesis: Implications for Cerebral Hemorrhage and Sporadic Creutzfeldt-Jakob Disease (1) 107–121
- Tripodis, Y., see Stern, R.A. (4) 1099–1109
- Trotta, L., see Migliaccio, R. (4) 1119–1130

- Tsai, R.M., see Wang, H.-F. (1) 227–236
- Tsz-Wa Ng, O., see Huang, C. (1) 213–226
- Turró-Garriga, O., J. Garre-Olmo, L. Calvó-Perxas, R. Reñé-Ramírez, J. Gascón-Bayarri and J.L. Conde-Sala, Course and Determinants of Anosognosia in Alzheimer’s Disease: A 12-Month Follow-up (2) 357–366
- Turrone, R., see Pilotto, A. (2) 563–570
- Ułamek-Kozioł, M., see Pluta, R. (4) 1023–1031
- Unverzagt, F.W., see Rattanabannakit, C. (4) 1145–1155
- Vaculovičová, M., see Adam, P. (3) 637–656
- Vaingankar, J.A., see Abdin, E. (2) 439–449
- Vallet, G.T., see Lavallée, M.M. (4) 1225–1236
- van Berckel, B.N.M., see Louwersheimer, E. (2) 581–590
- van den Hove, D.L.A., see Siersma, A.S.R. (3) 677–682
- van der Flier, W.M., see Louwersheimer, E. (2) 581–590
- van Leeuwen, F.W., see Siersma, A.S.R. (3) 677–682
- van Swieten, J.C., see Louwersheimer, E. (2) 581–590
- Vanacore, N., see Grande, G. (1) 57–67
- Vanderstichele, H., see Niemantsverdriet, E. (1) 97–106
- Vanmierlo, T., see Siersma, A.S.R. (3) 677–682
- Vasan, R.S., see Karakis, I. (2) 451–461
- Velázquez-Campos, G., see Morin, J.-P. (1) 69–79
- Venketasubramanian, N., see Chai, Y.L. (4) 1111–1118
- Verny, M., see Godefroy, O. (3) 815–825
- Vialaret, J., see Barthélémy, N.R. (4) 1033–1043
- Villemagne, V.L., see Ramanan, S. (2) 367–376
- Viña, J., see Bonet-Costa, V. (3) 701–711
- Vincent, A.J., see Southam, K.A. (3) 657–669
- Viola, V., see Serra, L. (2) 377–389
- Vrenken, H., see Louwersheimer, E. (2) 581–590
- Walker, D.G., see Dugger, B.N. (2) 345–356
- Wallon, D., see Grangeon, L. (3) 905–913
- Wang, C., see Wang, H.-F. (1) 227–236
- Wang, H.-F., L. Tan, L. Cao, X.-C. Zhu, T. Jiang, M.-S. Tan, Y. Liu, C. Wang, R.M. Tsai, J.-P. Jia, J.-T. Yu and Alzheimer’s Disease Neuroimaging Initiative, Application of the IWG-2 Diagnostic Criteria for Alzheimer’s Disease to the ADNI (1) 227–236
- Wang, H.-L., Y.-Y. Wang, X.-G. Liu, S.-H. Kuo, N. Liu, Q.-Y. Song and M.-W. Wang, Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer’s Disease: A Meta-Analysis (1) 45–55
- Wang, J., see Chai, Y.L. (4) 1111–1118
- Wang, M.-W., see Wang, H.-L. (1) 45–55
- Wang, Q., see Li, W.-X. (2) 417–425
- Wang, Q., see Yang, C.-c. (1) 33–44
- Wang, T.J., see Karakis, I. (2) 451–461
- Wang, Y.-Y., see Wang, H.-L. (1) 45–55
- Wattjes, M.P., see Louwersheimer, E. (2) 581–590
- White, M.T., L.M. Shaw, S.X. Xie, for the Alzheimer’s Disease Neuroimaging Initiative and the National Alzheimer’s Coordinating Center, Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer’s Disease (2) 463–470
- Whiteside, C.M., see Dugger, B.N. (2) 345–356
- Whittum-Hudson, J.A., see Itzhaki, R.F. (4) 979–984
- Wibom, M., see Smith, R. (2) 339–343
- Willcox, D.C., see Nishihira, J. (3) 857–866
- Witte, A.V., see Külzow, N. (3) 713–725
- Wohlschläger, A.M., see Pasquini, L. (1) 313–326
- Womack, K.B., see LoBue, C. (3) 727–736
- Wong, B.-S., see Chai, Y.L. (4) 1111–1118
- Wong, S., M. Bertoux, G. Savage, J.R. Hodges, O. Piguet and M. Hornberger, Comparison of Prefrontal Atrophy and Episodic Memory Performance in Dysexecutive Alzheimer’s Disease and Behavioral-Variant Frontotemporal Dementia (3) 889–903
- Woods, R.T., see Clare, L. (1) 139–150
- Woon, F.L., see LoBue, C. (3) 727–736
- Wu, X., see Xu, L. (4) 1045–1056
- Wu, Y., see Chang, L. (1) 197–212
- Wucherer, D., see Eichler, T. (3) 847–855
- Xiang, Q., see Lou, G. (4) 985–990
- Xiao, F., see Lou, G. (4) 985–990
- Xiao, M., see Xu, Z.-Q. (1) 179–195
- Xie, S.X., see White, M.T. (2) 463–470
- Xu, F., see Chu, S. (2) 525–532
- Xu, H., V.M. Perreau, K.A. Dent, A.I. Bush, D.I. Finkelstein and P.A. Adlard, Iron Regulates Apolipoprotein E Expression and Secretion in Neurons and Astrocytes (2) 471–487
- Xu, J., see Xu, Z.-Q. (1) 179–195
- Xu, L., X. Wu, R. Li, K. Chen, Z. Long, J. Zhang, X. Guo and L. Yao and for the Alzheimer’s Disease Neuroimaging Initiative, Prediction

- of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers (4) 1045–1056
- Xu, Z.-Q., H. Huang, Y.-L. Chen, Y.-Y. Gao, J. Xu, C. Marshall, Z.-Y. Cai and M. Xiao, Different Expression Patterns of Amyloid- β Protein Precursor Secretases in Human and Mouse Hippocampal Neurons: A Potential Contribution to Species Differences in Neuronal Susceptibility to Amyloid- β Pathogenesis (1) 179–195
- Yamamoto, Y., see Manousopoulou, A. (2) 333–338
- Yan, Z., see Chang, L. (1) 197–212
- Yang, C.-c., X.-x. Kuai, W.-b. Gao, J.-c. Yu, Q. Wang, L. Li and L. Zhang, Morroniside-Induced PP2A Activation Antagonizes Tau Hyperphosphorylation in a Cellular Model of Neurodegeneration (1) 33–44
- Yao, L., see Xu, L. (4) 1045–1056
- Yao, Q., G.-X. Jiang, Z.-M. Zhou, J.-M. Chen and Q. Cheng, Metabolic Syndrome and Mild Cognitive Impairment: A Case-Control Study among Elderly in a Shanghai Suburb (4) 1175–1182
- Yin, N.-N., see Hong, X.-P. (2) 605–617
- Yoon, H., see Song, J.M., (2) 591–604
- Yu, J.-c., see Yang, C.-c. (1) 33–44
- Yu, J.-T., see Wang, H.-F. (1) 227–236
- Yu, Q., see Fang, D. (2) 571–580
- Yuan, F., see Hong, X.-P. (2) 605–617
- Yuzawa, Y., see Sakai, K. (4) 997–1002
- Zanusso, G., see Costassa, E.V. (3) 875–887
- Zawia, N.H., see Masoud, A.M. (4) 1257–1264
- Zhang, J., see Stern, R.A. (4) 1099–1109
- Zhang, J., see Xu, L. (4) 1045–1056
- Zhang, L., see Yang, C.-c. (1) 33–44
- Zhang, Q., see Lou, G. (4) 985–990
- Zhang, Y., see Chang, L. (1) 197–212
- Zhang, Y.-H., see Hong, X.-P. (2) 605–617
- Zhang, Z., see Fang, D. (2) 571–580
- Zhou, W., see Chang, L. (1) 197–212
- Zhou, Z.-M., see Yao, Q. (4) 1175–1182
- Zhu, X.-C., see Wang, H.-F. (1) 227–236
- Zimmer, C., see Pasquini, L. (1) 313–326
- Zweig, J.A., see Gray, N.E. (2) 391–403